AIA Group Ltd grew its stake in United Therapeutics Corporation (NASDAQ:UTHR - Free Report) by 859.1% in the third quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission. The fund owned 10,425 shares of the biotechnology company's stock after acquiring an additional 9,338 shares during the period. AIA Group Ltd's holdings in United Therapeutics were worth $5,649,000 as of its most recent filing with the Securities and Exchange Commission.
Other institutional investors also recently modified their holdings of the company. Arjuna Capital boosted its position in United Therapeutics by 2.8% in the 1st quarter. Arjuna Capital now owns 662 shares of the biotechnology company's stock valued at $393,000 after buying an additional 18 shares during the last quarter. Sage Rhino Capital LLC raised its position in shares of United Therapeutics by 5.1% during the first quarter. Sage Rhino Capital LLC now owns 474 shares of the biotechnology company's stock worth $281,000 after acquiring an additional 23 shares during the last quarter. Bryn Mawr Trust Advisors LLC raised its position in shares of United Therapeutics by 5.4% during the first quarter. Bryn Mawr Trust Advisors LLC now owns 465 shares of the biotechnology company's stock worth $276,000 after acquiring an additional 24 shares during the last quarter. Meeder Advisory Services Inc. lifted its stake in shares of United Therapeutics by 4.1% during the first quarter. Meeder Advisory Services Inc. now owns 661 shares of the biotechnology company's stock valued at $392,000 after acquiring an additional 26 shares during the period. Finally, Kera Capital Partners Inc. lifted its stake in shares of United Therapeutics by 6.1% during the first quarter. Kera Capital Partners Inc. now owns 471 shares of the biotechnology company's stock valued at $279,000 after acquiring an additional 27 shares during the period. 94.08% of the stock is owned by institutional investors.
United Therapeutics Trading Up 1.2%
Shares of UTHR opened at $608.49 on Thursday. United Therapeutics Corporation has a 1 year low of $432.53 and a 1 year high of $614.23. The stock has a market cap of $26.10 billion, a P/E ratio of 21.77, a price-to-earnings-growth ratio of 4.35 and a beta of 0.49. The stock's 50-day moving average price is $532.33 and its two-hundred day moving average price is $532.45.
United Therapeutics (NASDAQ:UTHR - Get Free Report) last announced its quarterly earnings results on Wednesday, November 4th. The biotechnology company reported $5.71 EPS for the quarter, missing analysts' consensus estimates of $6.01 by ($0.30). The company had revenue of $832.50 million during the quarter, compared to the consensus estimate of $781.14 million. United Therapeutics had a net margin of 41.56% and a return on equity of 20.18%. The business's revenue was up 4.1% compared to the same quarter last year. During the same period last year, the company earned $7.16 earnings per share. As a group, equities analysts forecast that United Therapeutics Corporation will post 26.09 EPS for the current year.
United Therapeutics declared that its Board of Directors has initiated a stock repurchase plan on Thursday, October 22nd that permits the company to repurchase $2 billion in outstanding shares. This repurchase authorization permits the biotechnology company to purchase up to 8.3% of its stock through open market purchases. Share repurchase plans are typically a sign that the company's leadership believes its stock is undervalued.
Insider Transactions at United Therapeutics
In other United Therapeutics news, CEO Martine Rothblatt sold 9,500 shares of the company's stock in a transaction that occurred on Wednesday, August 19th. The shares were sold at an average price of $526.96, for a total value of $5,006,120.00. Following the completion of the sale, the chief executive officer owned 324,443 shares of the company's stock, valued at approximately $170,968,483.28. This represents a 2.84% decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through the SEC website. Insiders have sold a total of 393,228 shares of company stock worth $207,340,321 in the last ninety days. 8.60% of the stock is currently owned by insiders.
Trending Headlines about United Therapeutics
Here are the key news stories impacting United Therapeutics this week:
- Positive Sentiment: Third-quarter revenue rose 4.1% year over year to $832.5 million, beating analyst expectations of about $781 million. Management said the company is entering a period of stronger growth and advancing new therapies. United Therapeutics Q3 2026 results
- Positive Sentiment: BTIG raised its price target to $768 from $728 and maintained a Buy rating, signaling continued analyst confidence in the shares. BTIG Research ratings
- Positive Sentiment: The company announced a buyout of Pfizer’s royalty rights tied to ralinepag, a lung-disease therapy. Ending those royalties could improve the drug’s future economics, though the announcement details provided no financial terms. Ralinepag royalty buydown announcement
- Negative Sentiment: Adjusted earnings were a weak spot: EPS of $5.71 missed the approximately $6.01 consensus and fell from $7.16 a year earlier. Reports also noted lower net income. Q3 earnings miss
- Neutral Sentiment: CEO Martine Rothblatt sold 9,500 shares, reducing her direct holding by 2.84%. She retained 324,443 shares; the sale may draw investor attention but does not by itself establish a change in the company’s outlook. United Therapeutics insider trades
Analyst Upgrades and Downgrades
Several equities analysts recently issued reports on the company. Raymond James Financial set a $720.00 price target on United Therapeutics in a report on Wednesday. Morgan Stanley boosted their price objective on United Therapeutics from $515.00 to $566.00 and gave the stock an "equal weight" rating in a report on Wednesday, October 7th. Jefferies Financial Group restated a "buy" rating and set a $728.00 target price on shares of United Therapeutics in a research report on Wednesday, October 14th. Weiss Ratings lowered shares of United Therapeutics from a "buy (b)" rating to a "buy (b-)" rating in a research note on Thursday, August 27th. Finally, The Goldman Sachs Group reiterated a "sell" rating and set a $368.00 price target on shares of United Therapeutics in a research report on Thursday, October 15th. Thirteen equities research analysts have rated the stock with a Buy rating, two have issued a Hold rating and one has issued a Sell rating to the company's stock. According to MarketBeat.com, United Therapeutics currently has a consensus rating of "Moderate Buy" and an average target price of $674.00.
Check Out Our Latest Research Report on United Therapeutics
About United Therapeutics
(
Free Report)
United Therapeutics Corporation is a biotechnology company focused on developing and commercializing therapies for patients with life-threatening conditions, particularly pulmonary arterial hypertension (PAH). The company's portfolio includes Tyvaso and Tyvaso DPI, inhaled formulations of treprostinil; Remodulin, an injectable treprostinil product; and Orenitram, an oral treprostinil therapy. These treatments are designed to improve exercise ability and delay disease progression in people with PAH.
The company also markets Unituxin, an antibody therapy used as part of treatment for high-risk neuroblastoma, a type of childhood cancer.
Featured Stories

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.
Before you consider United Therapeutics, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and United Therapeutics wasn't on the list.
While United Therapeutics currently has a Moderate Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
The AI boom is creating opportunities across semiconductors, cloud computing, enterprise software, infrastructure, cybersecurity, and automation.
Inside this report, you’ll find 10 companies positioned to benefit as artificial intelligence moves from hype to real-world deployment and becomes a core growth driver for corporate America.
Get This Free Report
Continue following MarketBeat
Add MarketBeat as your preferred source on Google to see our latest stories in your feed.
Like this article? Share it with a colleague.
Link copied to clipboard.